Business Wire

DEWIZ-GOLF

Share
Jesper Kärrbrink Appointed Chairman of deWiz Golf

deWiz Golf’s Board, including co-founders Christian Bergh and Markus Westerberg, has announced that Jesper Kärrbrink has been appointed new Chairman of the Board. Kärrbrink brings extensive experience from company leadership roles, currently as chairman of Green Jade Games and previously as CEO of, among others, Svenska Spel, Eniro, Euroflorist, Mr. Green, and Östersunds-Posten.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005415/en/

“On behalf of my co-founder Markus and deWiz's board, it is with great pride that I announce that Jesper has been appointed deWiz's new chairman of the board,” said Christian Bergh, co-founder and COO of deWiz Golf. “After five years of development and research, this has been an exciting year with the launch of deWiz and the future is even more exciting with executives like Jesper helping us guide us towards our strategic vision to revolutionize golf and other sports using our world-class wearable technology. Jesper's global experience will be of great value as deWiz expands across golf-rich markets, including North America, Europe and Asia.”

Launched this summer, deWiz is based on revolutionary wearable technology that combines capturing high-precision data of a golfer's swing in real time and biometric feedback to increase a golfer's pace of learning and consistency.

“deWiz is the perfect example of how technology can help players improve their golf game - at all levels,” said Jesper Kärrbrink, new chairman of deWiz Golf. “Artificial intelligence, data collection and motion sensors have been used for a long time to help elite athletes improve their performance. And what's really fascinating about deWiz is how it delivers this high-tech approach at my level, as a dedicated amateur golfer, through a wearable device that helps me to improve my game anywhere, whether I'm on the course, on the range or practicing on my swing at home.”

Today, golfers in the EU, North America and South Korea can buy deWiz and the company plans to expand with new markets in 2022, including Japan, Australia and South Africa.

DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz has been under development for more than five years and has attracted an impressive list of ambassadors, including Bryson DeChambeau, U.S. Open champion from 2020; Annika Sorenstam, 10-time major-champion; Vijay Singh, 3-time major-champion; Lydia Ko, 2-time major champion; 2016 Open-champion Henrik Stenson; 2019 Houston Open-champion Lanto Griffin; and 2-time world champion in long drive, Tim Burke. deWiz's user-friendly app and wearable technology tracks the exact position of a golfer's hands throughout the swing, providing a 3D analysis and delivers data showing Transition , Backswing Length , Wedge Distance and Tempo . These unique deWiz data points provide measurable values ​​that any avid golfer, professional teacher or world-class player can use to effectively refine their swing. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world increase their enjoyment of the game through innovative technology that increases their pace of learning. At the moment, deWiz sells for $699 and is available in the U.S., Canada, Europe and South Korea (more markets are opening regularly - visit the site for the latest updates). Visit dewizgolf.com for more information on how to improve your swing faster or download the app to demonstrate its features via the Apple App Store or Google Play.

Link:

ClickThru

Social Media:

https://www.facebook.com/dewizgolf

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye